Table of contents


On 20 February 2007, orphan designation (EU/3/07/432) was granted by the European Commission to Quintiles UK Limited, United Kingdom, for ex-vivo cultured adult human mesenchymal stem cells for the treatment of graft-versus-host disease.

The sponsorship was transferred to Genzyme Europe BV, the Netherlands, in October 2009 and to Voisin Consulting S.A.R.L., France, in February 2013.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
Ex-vivo cultured adult human mesenchymal stem cells
Disease / condition
Treatment of graft-versus-host disease
Date of decision
Orphan decision number

Sponsor's contact details

Voisin Consulting S.A.R.L.
64 Avenue Pierre Grenier
92100 Boulogne-Billancourt
Tel. +33 1413 18300

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating